Atrial Fibrillation in Kidney Failure: Challenges in Risk Assessment and Anticoagulation Management.

ABSTRACT: Management of atrial fibrillation (AF) is a clinical conundrum in people with kidney failure. Stroke risk is disproportionately high, but clinicians have a limited armamentarium to improve outcomes in this population in whom there is a concurrently high bleeding risk. Direct oral anticoagulants may have a superior benefit-risk profile compared with vitamin K antagonists in people on hemodialysis. Although research has predominantly focused on identifying a safe and effective oral anticoagulation option to reduce stroke risk in people with kidney failure (and predominantly those on hemodialysis), it remains uncertain how clinicians discriminate between people who would derive net clinical benefit as opposed to net harm. The recommended CHA₂DS_2-VASc score cutoffs provid

SUBMITTER: Law MM 

PROVIDER: S-EPMC10403723 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature